1097920-74-5

Basic information

• Product Name: 4-chloro-N-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazin-2-amine
• Synonyms: 4-chloro-N-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazin-2-amine
• CAS NO: 1097920-74-5
• Molecular Weight: 312.78
• Mol File: 1097920-74-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 4-chloro-N-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-N-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazin-2-amine(1097920-74-5)
• EPA Substance Registry System: 4-chloro-N-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazin-2-amine(1097920-74-5)

Safety Data

• Hazardous Substances Data: 1097920-74-5(Hazardous Substances Data)

Upstream product

• 2831-66-5 2,4-dichloro-1,3,5-triazine 
• 76697-50-2 1-amino-2-(isopropylsulphonyl)benzene 

Downstream Products

• 1097917-15-1 N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)-piperidin-1-yl]phenyl}-N′-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine 
• 1097917-81-1 N-[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-methoxyphenyl]-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine 
• 1097917-68-4 1-[3-methoxy-4-({4-[2-(propane-2-sulfonyl)anilino]-1,3,5-triazin-2-yl}amino)phenyl]piperidin-4-one 
• 1097918-72-3 N-{4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-(propan-2-yloxy)phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine 
• 1097918-71-2 N-{2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine 
• 1097919-24-8 N-{2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine 

Relevant articles and documents

Improved Manufacturing Route and Polymorphic Control of a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor ASP3026

Our effort toward the process improvement of anaplastic lymphoma kinase (ALK) inhibitor ASP3026 (1) is described. A cost-effective and practical synthesis of 1 was accomplished as a result of the change of starting material from 2,4-dichloro-1,3,5-triazine (6) to cyanuric chloride (9) and late-stage introduction of a highly reactive N-methyl piperazine moiety by reductive amination of intermediate ketone 13. The modified process avoided the challenges with the original synthesis and furnished the several hundred kilograms of high-quality API with high economic efficiency, operability, and reproducibility. Furthermore, a sequence of investigation of polymorphic control in the second-generation synthetic route to obtain the thermodynamically desired, most stable polymorph Form A04 is also discussed.

Discovery of N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N′-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a potent and selective anaplastic lymphoma kinase (ALK) inhibitor

Anaplastic lymphoma kinase (ALK) is a validated therapeutic target for treating echinoderm microtubule- associated protein-like 4 (EML4)-ALK positive non-small cell lung cancer (NSCLC). We synthesized a series of 1,3,5-triazine derivatives and identified ASP3026 (14a) as a potent and selective ALK inhibitor. In mice xenografted with NCI-H2228 cells expressing EML4-ALK, once-daily oral administration of 14a demonstrated dose-dependent antitumor activity. Here, syntheses and structure-activity relationship (SAR) studies of 1,3,5-triazine derivatives are described.

Triazine derivative anaplastic lymphoma kinase inhibitor

The invention belongs to the technical field of medicines, and particularly relates to a triazine derivative anaplastic lymphoma kinase inhibitor shown in a general formula (I), pharmaceutically acceptable salt, ester, solvate or stereoisomer of the inhibitor. R1, R2, R3, R4, R6, R7 and A rings are defined in the description. The invention further relates to a preparation method of compounds, a medicinal preparation containing the compounds, a medicine combination containing the compounds and an application of the compounds, the pharmaceutically acceptable salt, ester, solvate or stereoisomer to preparation of a medicine for treating and/or preventing anaplastic lymphoma kinase-mediated cancer-related diseases.